California 2017-2018 Regular Session

California Senate Bill SB1021

Introduced
2/7/18  
Introduced
2/7/18  
Refer
2/14/18  
Refer
2/14/18  
Refer
4/16/18  
Report Pass
4/30/18  
Report Pass
4/30/18  
Refer
5/1/18  
Refer
5/1/18  
Report Pass
5/22/18  
Report Pass
5/22/18  
Engrossed
5/29/18  
Engrossed
5/29/18  
Refer
6/4/18  
Refer
6/4/18  
Refer
6/14/18  
Refer
6/14/18  
Report Pass
6/20/18  
Report Pass
6/20/18  
Refer
6/20/18  
Refer
8/6/18  
Refer
8/6/18  
Report Pass
8/16/18  
Report Pass
8/16/18  
Enrolled
8/28/18  
Enrolled
8/28/18  
Chaptered
9/26/18  
Passed
9/26/18  

Caption

Prescription drugs.

Impact

If enacted, SB 1021 will significantly impact how health plans determine copayment structures for outpatient prescription drugs, regulating that no insured person pays more than the retail price of a medication if it is lower than the copayment. The bill also extends coverage mandates for combination antiretroviral treatments, underscoring California's commitment to treating and preventing AIDS/HIV. By prohibiting variations in formularies that discourage enrollment among individuals with health conditions, the bill supports equitable health access.

Summary

Senate Bill 1021, sponsored by Senator Wiener, seeks to amend existing regulations concerning prescription drugs under California's health care laws. Central to the bill is the prohibition against health care service plans and health insurers from having a drug formulary that contains more than four tiers. The bill intends to ensure that patients are not discouraged from enrolling in health plans due to high costs associated with necessary medications. Furthermore, it extends existing provisions that cap copayments for outpatient prescription drugs.

Sentiment

The sentiment around SB 1021 appears largely supportive among advocacy groups and those representing vulnerable communities who may struggle with high prescription drug costs. Proponents argue that it is a critical step toward bolstering access to necessary health care and ensuring that individuals with chronic conditions do not face additional barriers. Critics, however, may voice concerns regarding the implications for insurers' flexibility in managing prescription drug benefits and the potential strain on resources.

Contention

One notable point of contention is the potential crime designation attached to willful violations of the bill's stipulations. The bill's implications for local agency expenses have also been addressed, clarifying that no reimbursement will be required for costs stemming from new crime definitions or penalties. This provision is particularly important as it exempts local agencies from financial liability while focusing on the health care coverage impacts for individuals across the state.

Companion Bills

No companion bills found.

Similar Bills

CA SB621

Health care coverage: biosimilar drugs.

CA AB1880

Prior authorization and step therapy.

CA AB2144

Health care coverage: step therapy.

CA AB347

Health care coverage: step therapy.

CA AB948

Prescription drugs.